

August 02, 2024

The Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400001
BSE Scrip Code: 543427

The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C/1, G Block,
Bandra - Kurla Complex
Bandra (East), Mumbai – 400051
NSE Symbol: MEDPLUS

Dear Sir/Madam,

Sub: Outcome of Board meeting held today i.e August 02, 2024, pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015 of the Company

With reference to our letter dated June 27, 2024, the Board of Directors at their meeting held today i.e. August 02, 2024, approved the followings:

1. The Un-audited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2024 along with Limited Review Report received from the Statutory Auditors of the Company.
2. The Board of Director's Report, Management Discussion and Analysis Report, Corporate Governance Report and Business Responsibility and Sustainability Report for the year ended March 31, 2024.
3. Taking note of Secretarial Audit Report of the Company and its material subsidiary Companies for the F.Y 2023-24.
4. Notice of 18th Annual General Meeting scheduled to be held on Thursday, September 26, 2024 and cut-off date to ascertain the eligible shareholders for e-voting.
5. Appointment of Kfin Technologies Limited (RTA) to facilitate the e-voting process and appointment of Ms. Rashida Adenwala Practicing Company Secretary (FCS No. 4020) as scrutinizer for e-voting process
6. Recommendation for ratification of remuneration of M/s MPR & Associates, Cost Accountant as Cost Auditor of the Company for the financial year 2023-24 and 2024-25
7. Appointment of M/s R&A Associates as the Secretarial Auditors of the Company for the Financial Year 2024-25

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Limited Review Report received from B S R and Co, the Statutory Auditors of the company the Unaudited Standalone and Consolidated Financial Results as mentioned at serial nos. 1 is enclosed herewith.

The meeting commenced at 03:30 PM and concluded at 05:20 PM.

Kindly take note of the same. The above information is also available on the Company's website.

For MedPlus Health Services Limited


Manoj Kumar Srivastava
Company Secretary & Compliance Officer
FCS-7460



Encl: a/a

Limited Review Report on unaudited consolidated financial results of MedPlus Health Services Limited for the quarter ended 30 June 2024 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**To the Board of Directors of MedPlus Health Services Limited**

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of MedPlus Health Services Limited (hereinafter referred to as "the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 30 June 2024 ("the Statement") (in which are included interim financial information of Medplus Employee Benefit Trust ("Trust"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations")).
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the entities mentioned in Annexure I to the Statement.
5. Attention is drawn to the fact that the figures for the three months ended 31 March 2024 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
6. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Principal Office:

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center,
Western Express Highway, Goregaon (East), Mumbai - 400063

Limited Review Report (Continued)

MedPlus Health Services Limited

7. We did not review the interim financial results of 2 subsidiaries included in the Statement, whose interim financial results reflects total revenues (before consolidation adjustments) of Rs.2,471.38 million, total net profit after tax (before consolidation adjustments) of Rs.16.20 million and total comprehensive income (before consolidation adjustments) of Rs.16.20 million, for the quarter ended 30 June 2024, as considered in the Statement. These interim financial results have been reviewed by other auditor whose reports have been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter.


8. The Statement includes the interim financial results of 9 subsidiaries which have not been reviewed, whose interim financial results reflects total revenues (before consolidation adjustments) of Rs.824.19 million, total net profit after tax (before consolidation adjustments) of Rs.1.80 million and total comprehensive income (before consolidation adjustments) of Rs.1.80 million, for the quarter ended 30 June 2024, as considered in the Statement. According to the information and explanations given to us by the Parent's management, these interim financial results are not material to the Group.

Our conclusion is not modified in respect of this matter.

For **B S R and Co**

Chartered Accountants

Firm's Registration No.:128510W



Arpan Jain

Partner

Hyderabad

02 August 2024

Membership No.: 125710

UDIN:24125710BKFZOL3860

Limited Review Report (Continued)

MedPlus Health Services Limited

Annexure I

List of entities included in unaudited consolidated financial results.

Sr. No	Name of Entities	Relationship
1	MedPlus Health Services Limited	Holding Company
2	Optival Health Solutions Private Limited	Subsidiary
3	MHS Pharmaceuticals Private Limited	Subsidiary
4	Nova Sud Pharmaceuticals Private Limited	Subsidiary
5	Wynclark Pharmaceuticals Private Limited	Subsidiary
6	Kalyani Meditimes Private Limited	Subsidiary
7	Clearancekart Private Limited	Subsidiary
8	Sai Sridhar Pharma Private Limited	Subsidiary
9	Venkata Krishna Enterprises Private Limited	Subsidiary
10	Shri Banashankari Pharma Private Limited	Subsidiary
11	Deccan Medisales Private Limited	Subsidiary
12	Sidson Pharma Distributors Private Limited	Subsidiary
13	MedPlus Insurance Brokers Private Limited	Subsidiary

h

MedPlus Health Services Limited

CIN - L85110TG2006PLC051845

Registered Office: H.No:11-6-56, Survey No: 257 & 258/1, Opp: IDPL Railway Siding Road, Moosapet, Kukatpally, Hyderabad 500037

Statement of Unaudited Consolidated Financial Results for the Quarter ended June 30, 2024

(Rs. in Millions)

S. No.	Particulars	Quarter ended			Year ended
		June 30, 2024	March 31, 2024	June 30, 2023	March 31, 2024
		Unaudited	Refer note 4	Unaudited	Audited
	Income				
	Revenue from operations	14,888.25	14,904.98	12,842.96	56,248.55
	Other income	87.12	104.59	93.93	400.08
I	Total income	14,975.37	15,009.57	12,936.89	56,648.63
	Expenses				
	Cost of materials consumed	123.78	122.45	99.07	445.30
	Purchases of stock-in-trade	12,458.43	11,633.10	10,419.44	45,378.53
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(986.52)	(216.58)	(409.58)	(1,907.55)
	Employee benefits expense	1,618.22	1,606.00	1,475.98	6,255.19
	Finance costs	246.58	251.26	232.71	964.33
	Depreciation and amortisation expense	600.30	592.15	524.15	2,242.14
	Other expenses	736.71	701.34	544.61	2,536.26
II	Total expenses	14,797.50	14,689.72	12,886.38	55,914.20
III	Profit before tax (I-II)	177.87	319.85	50.51	734.43
	Tax expense				
	- Current tax expense	60.44	86.82	29.26	271.03
	- Deferred tax benefit	(26.01)	(102.58)	(16.40)	(192.37)
IV	Total tax expense / (benefit)	34.43	(15.76)	12.86	78.66
V	Profit after tax (III-IV)	143.44	335.61	37.65	655.77
	Other Comprehensive Income (OCI)				
	(i) Items that will not be reclassified to profit or loss				
	- Re-measurement gain / (loss) on employee defined benefit plan	-	(43.95)	-	0.02
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	8.11	-	(0.57)
VI	Other comprehensive income / (loss) for the period/year, net of tax	-	(35.84)	-	(0.55)
VII	Total comprehensive income for the period/year (V+VI)	143.44	299.77	37.65	655.22
VIII	Profit for the period/year attributable to:				
	Shareholders of the Company	143.63	333.96	37.86	654.73
	Non-controlling interest	(0.19)	1.65	(0.21)	1.04
		143.44	335.61	37.65	655.77
IX	Total comprehensive income attributable to:				
	Shareholders of the Company	143.63	298.12	37.86	654.18
	Non-controlling interest	(0.19)	1.65	(0.21)	1.04
		143.44	299.77	37.65	655.22
X	Paid-up Capital				
	Equity Share Capital	239.09	239.07	238.61	239.07
XI	Other Equity				15,540.25
XII	Earnings per equity share (refer note 5)				
	Basic (In absolute Rs.)	1.20	2.81	0.32	5.48
	Diluted (In absolute Rs.)	1.20	2.79	0.32	5.45
XIII	Face value per share				
	Equity shares (In absolute Rs.)	2.00	2.00	2.00	2.00



Notes to the Unaudited consolidated financial results:

1. The above unaudited consolidated financial results of MedPlus Health Services Limited ('The Company') and its subsidiaries (together referred as 'The Group') have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("listing regulations") from time to time. These unaudited consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on August 02, 2024. These financial results have been subjected to limited review by the Statutory Auditors of the Company and the auditors have expressed and issued an unmodified review report on the same.
2. During the year ended March 31, 2022, the Company has completed its Initial Public Offering (IPO) of 17,573,342 equity shares of face value of Rs. 2 each for cash at an issue price of Rs. 796 per equity share aggregating to Rs. 13,982.95 million, consisting of Fresh Issue of 7,544,511 equity shares amounting to Rs. 6,000 million and an offer for sale of 10,028,831 equity shares amounting to Rs. 7,982.95 million by the Selling Shareholders. Pursuant to the IPO, the equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) with effect from 23 December 2021.

The utilization of IPO proceeds received by the Company (net of IPO related expense) is summarized below:

(Rs. In Millions)

Objects as per Prospectus	Planned utilisation as per Prospectus	Utilisation up to June 30, 2024	Unutilised amount as on June 30, 2024*
i) Investment in Subsidiary - Optival Health Solutions Private Limited towards their working capital requirements	4,671.70	4,671.70	-
ii) General Corporate Purposes	1,111.03	448.53	662.50
Total	5,782.73	5,120.23	662.50


* The aforesaid unutilised proceeds of Rs. 662.50 million have been placed as fixed deposits with bank.

3. During the year ended March 31, 2024, with respect to the merger between the Company and MHS Pharmaceuticals Private Limited (MHS), a wholly owned subsidiary, the Company has received approval from equity shareholders and trade creditors at their meetings held on December 15, 2023 pursuant to NCLT order dated November 7, 2023. The Company has filed the final petition with the NCLT for approval under Section 232 Read with Section 230 of the Companies Act, 2013 dated December 26, 2023. The final order is awaited from NCLT. Consequent adjustments in the financial statements will be made on receipt of requisite order.
4. The Consolidated figures for the quarter ended March 31, 2024 are the balancing figures between audited figures in respect of the full financial year and the published unaudited year to date figures upto the third quarter of said financial year.
5. The earnings per equity share for the quarters are not annualised.



6. During the quarter and year ended 31 March 2024, pursuant to an assessment of future profitability of the operations of the Holding Company, the management has recognized deferred tax assets amounting to Rs. 33.59 million on unused business losses and unabsorbed depreciation of earlier years.
7. The above financial results are also available at the Stock Exchange's website i.e. www.bseindia.com, www.nseindia.com and the Company's website www.medplusindia.com.

For and on behalf of the Board of Directors of
MedPlus Health Services Limited



G.Madhukar Reddy

Managing Director and Chief Executive Officer
DIN: 00098097



Place: Hyderabad

Date: August 02, 2024

**Segment information under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
for the Quarter ended June 30, 2024**

(Rs. In Millions)

Particulars	Quarter Ended			Year Ended
	June 30, 2024	March 31, 2024	June 30, 2023	March 31, 2024
	Unaudited	Refer note 4	Unaudited	Audited
1. Segment revenue				
a. Retail	14,643.58	14,667.68	12,701.88	55,490.52
b. Diagnostic services	242.43	232.32	138.99	748.85
c. Others	2.24	4.98	2.09	9.18
Revenue from operations	14,888.25	14,904.98	12,842.96	56,248.55
2. Segment results profit / (loss)				
a. Retail	195.29	347.66	106.96	916.25
b. Diagnostic services	(42.90)	(59.78)	(95.64)	(318.10)
c. Others	0.66	3.26	(0.04)	1.16
Total	153.05	291.14	11.28	599.31
Less: Unallocable Finance cost	-	(0.65)	-	(0.65)
Add: Unallocable other income	24.82	29.36	39.23	135.77
Total profit before tax	177.87	319.85	50.51	734.43
3. Segment assets				
a. Retail	27,602.18	26,171.18	24,367.88	26,171.18
b. Diagnostic services	1,478.32	1,633.34	1,790.61	1,633.34
c. Unallocated	2,171.00	2,243.49	2,351.16	2,243.49
Total	31,251.50	30,048.01	28,509.65	30,048.01
4. Segment liabilities				
a. Retail	14,406.23	13,309.03	12,648.13	13,309.03
b. Diagnostic services	892.61	963.63	863.48	963.63
c. Unallocated	5.54	1.76	12.32	1.76
Total	15,304.38	14,274.42	13,523.93	14,274.42



Limited Review Report on unaudited standalone financial results of MedPlus Health Services Limited for the quarter ended 30 June 2024 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of MedPlus Health Services Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of MedPlus Health Services Limited (hereinafter referred to as "the Company") for the quarter ended 30 June 2024 ("the Statement") (in which are included interim financial information of Medplus Employee Benefit Trust ("Trust")).
2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Attention is drawn to the fact that the figures for the three months ended 31 March 2024 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it



Principal Office:

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center,
Western Express Highway, Goregaon (East), Mumbai - 400063

B S R and Co

Limited Review Report (Continued)


MedPlus Health Services Limited

contains any material misstatement.

For **B S R and Co**

Chartered Accountants

Firm's Registration No.:128510W



Arpan Jain

Partner

Hyderabad

02 August 2024

Membership No.: 125710

UDIN:24125710BKFZOM2268

MedPlus Health Services Limited


CIN - L85110TG2006PLC051845

Registered Office: H.No:11-6-56, Survey No: 257 & 258/1, Opp: IDPL Railway Siding Road, Moosapet, Kukatpally, Hyderabad 500037

Statement of Unaudited Standalone Financial Results for the Quarter ended June 30, 2024

(Rs. in Millions)

S. No	Particulars	Quarter ended			Year ended
		June 30, 2024	March 31, 2024	June 30, 2023	March 31, 2024
		Unaudited	Refer note 5	Unaudited	Audited
	Income				
	Revenue from operations	1,783.26	1,483.68	718.92	4,670.30
	Other income	18.40	18.98	18.07	72.93
I	Total income	1,801.66	1,502.66	736.99	4,743.23
	Expenses				
	Cost of materials consumed	123.77	119.67	99.00	445.23
	Purchases of stock-in-trade	1,265.24	1,010.69	422.24	3,073.95
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	2.14	(6.26)	(5.34)	(8.83)
	Employee benefits expense	112.30	116.75	97.58	436.06
	Finance costs	20.99	21.09	20.79	84.02
	Depreciation and amortisation expense	64.74	64.02	55.37	241.70
	Other expenses	96.39	113.48	82.20	400.69
II	Total expenses	1,685.57	1,439.44	771.84	4,672.82
III	Profit / (Loss) before tax (I-II)	116.09	63.22	(34.85)	70.41
	Tax expense				
	- Current tax expense / (benefit)	28.68	(0.89)	-	9.65
	- Deferred tax benefit	(5.15)	(35.05)	-	(35.05)
IV	Total tax expense / (benefit)	23.53	(35.94)	-	(25.40)
V	Net Profit / (Loss) after tax (III-IV)	92.56	99.16	(34.85)	95.81
	Other comprehensive income				
	(i) Items that will not be reclassified to profit or loss				
	- Re-measurement gain / (loss) on employee defined benefit plan	-	(3.69)	-	5.81
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	(1.46)	-	(1.46)
VI	Other comprehensive income / (loss) for the period / year, net of tax	-	(5.15)	-	4.35
VII	Total comprehensive income / (loss) for the period / year (V+VI)	92.56	94.01	(34.85)	100.16
VIII	Paid-up capital				
	Equity share capital	239.09	239.07	238.61	239.07
IX	Other Equity				11,487.23
X	Earnings / (Loss) per equity share (refer note 6)				
	Basic (In absolute Rs.)	0.77	0.83	(0.29)	0.80
	Diluted (In absolute Rs.)	0.77	0.83	(0.29)	0.80
XI	Face value per share				
	Equity shares (In absolute Rs.)	2.00	2.00	2.00	2.00
	CCPS considered as equity (Rs.)	-	-	-	-



Notes to the Unaudited standalone financial results:

1. The above unaudited standalone financial results of MedPlus Health Services Limited ('The Company') have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("listing regulations") from time to time. These unaudited standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on August 02, 2024. These financial results have been subjected to limited review by the Statutory Auditors of the Company and the auditors have expressed and issued an unmodified review report on the same.
2. During the year ended March 31, 2022, the Company has completed its Initial Public Offering (IPO) of 17,573,342 equity shares of face value of Rs. 2 each for cash at an issue price of Rs. 796 per equity share aggregating to Rs. 13,982.95 million, consisting of Fresh Issue of 7,544,511 equity shares amounting to Rs. 6,000 million and an offer for sale of 10,028,831 equity shares amounting to Rs. 7,982.95 million by the Selling Shareholders. Pursuant to the IPO, the equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) with effect from 23 December 2021.


The utilization of IPO proceeds received by the Company (net of IPO related expense) is summarized below:

(Rs. In Millions)

Objects as per Prospectus	Planned utilisation as per Prospectus	Utilisation up to June 30, 2024	Unutilised amount as on June 30, 2024*
i) Investment in Subsidiary - Optival Health Solutions Private Limited towards their working capital requirements	4,671.70	4,671.70	-
ii) General Corporate Purposes	1,111.03	448.53	662.50
Total	5,782.73	5,120.23	662.50

* The aforesaid unutilised proceeds of Rs. 662.50 million have been placed as fixed deposits with bank.

3. As per Ind AS 108 'Operating segments', the Company has disclosed the segment information only as part of the consolidated financial results.
4. During the year ended March 31, 2024, with respect to the merger between the Company and MHS Pharmaceuticals Private Limited (MHS), a wholly owned subsidiary, the Company has received approval from equity shareholders and trade creditors in a meeting held on December 15, 2023 pursuant to NCLT order dated November 7, 2023. The Company has filed the final petition with the NCLT for approval under Section 232 Read with Section 230 of the Companies Act, 2013 dated December 26, 2023. The final order is awaited from NCLT. Consequent adjustments in the financial statements will be made on receipt of requisite order.
5. The standalone figures for the quarter ended March 31, 2024 are the balancing figures between audited figures in respect of the full financial year and the published unaudited year to date figures upto the third quarter of said financial year.
6. The earnings per equity share for the quarters are not annualised.



7. During the quarter and year ended 31 March 2024, pursuant to an assessment of future profitability of the operations of the Company, the management has recognized deferred tax assets amounting to Rs. 33.59 million on unused business losses and unabsorbed depreciation of earlier years.
8. The above financial results are also available at the Stock Exchange's website i.e. www.bseindia.com, www.nseindia.com and the Company's website www.medplusindia.com.

For and on behalf of the Board of Directors of
MedPlus Health Services Limited

G.Madhukar Reddy

Managing Director and Chief Executive Officer
DIN: 00098097



Place: Hyderabad

Date: August 02, 2024